{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:22:06Z","timestamp":1769116926399,"version":"3.49.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Venous thromboembolism (VTE) is a leading cause of cardiovascular morbidity and mortality. Evidence directly comparing direct oral anticoagulants (DOACs) with placebo for extended anticoagulation is limited. We conducted this systematic review and meta-analysis following Preferred Reporting Items for Systematic Review and Meta-Analyses and Cochrane guidelines. We identified randomized controlled trials that compared DOACs with placebo for extended VTE therapy in PubMed, Cochrane Library, and ClinicalTrials.gov up to October 2025. We calculated pooled risk ratios (RR) with 95% confidence intervals (CI) using a random-effects model. We assessed risk of bias using the Cochrane tool and evaluated certainty of evidence with\n                    <jats:bold>Grading of Recommendations, Assessment, Development and Evaluation<\/jats:bold>\n                    (GRADE) methodology. Four randomized controlled trials (n = 5621) met the inclusion criteria. DOACs significantly reduced all-cause mortality (RR, 0.38; 95% CI, 0.19\u20130.76;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.006) and VTE recurrence (RR, 0.17; 95% CI, 0.12\u20130.24;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001). DOACs did not significantly increase the incidence of major bleeding compared to placebo (RR, 1.84; 95% CI, 0.33\u201310.21;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.48), but they increased clinically relevant nonmajor bleeding (RR, 3.13; 95% CI, 2.23\u20134.39;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001). Extended DOAC therapy reduces VTE recurrence and mortality, with no significant increase in major bleeding but a higher risk of clinically relevant nonmajor bleeding. Patients at low bleeding risk benefit most from carefully selected long-term DOAC use.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000001175","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:00:55Z","timestamp":1769058055000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1097","author":[{"given":"Muhammad","family":"Waqas","sequence":"first","affiliation":[{"name":"Department of Medicine, Wah Medical College, Wah Cantt, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ziauddin University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maimoona","family":"Nasir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ziauddin University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Khalid","family":"Afridi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Ahmed","family":"Waqas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"R1-20260122","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjms.2016.03.018","article-title":"A comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism.","volume":"352","author":"Comerota","year":"2016","journal-title":"Am J Med Sci"},{"key":"R2-20260122","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11239-019-01878-x","article-title":"Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.","volume":"48","author":"Giustozzi","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"R3-20260122","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.","volume":"41","author":"Burnett","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R4-20260122","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11739-016-1521-8","article-title":"Safety and efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.","volume":"11","author":"Imberti","year":"2016","journal-title":"Intern Emerg Med"},{"key":"R5-20260122","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.","volume":"16","author":"Vasanthamohan","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R6-20260122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jep.13194","article-title":"Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.","volume":"26","author":"Djulbegovic","year":"2020","journal-title":"J Eval Clin Pract"},{"key":"R8-20260122","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R9-20260122","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R12-20260122","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R13-20260122","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism.","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-20260122","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"R15-20260122","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism.","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R16-20260122","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism.","volume":"393","author":"Piazza","year":"2025","journal-title":"N Engl J Med"},{"key":"R17-20260122","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3810\/pgm.2010.03.2122","article-title":"Venous thromboembolism: a clinical review.","volume":"122","author":"Osinbowale","year":"2010","journal-title":"Postgrad Med"},{"key":"R18-20260122","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"R19-20260122","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00108-010-2725-z","article-title":"Neue orale Antikoagulanzien: Werden sie die Vitamin-K-Antagonisten verdr\u00e4ngen? [New oral anticoagulants: better than vitamin K antagonists?].","volume":"51","author":"V\u00f6ller","year":"2010","journal-title":"Internist (Berl)"},{"key":"R20-20260122","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"key":"R21-20260122","doi-asserted-by":"crossref","first-page":"JC42","DOI":"10.7326\/ACPJ201910150-042","article-title":"Review: extended therapy with DOACs, but not VKAs, reduces mortality after VTE treated with initial anticoagulation.","volume":"171","author":"Donato","year":"2019","journal-title":"Ann Intern Med"},{"key":"R22-20260122","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1076029616670259","article-title":"Patients with a history of idiopathic deep venous thrombosis have long-term increased levels of inflammatory markers and markers of endothelial damage.","volume":"23","author":"Jezovnik","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"R23-20260122","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0039-1692703","article-title":"Current and emerging direct oral anticoagulants: state-of-the-art.","volume":"45","author":"Lippi","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"R24-20260122","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.04.036","article-title":"Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE.","volume":"191","author":"Bounameaux","year":"2020","journal-title":"Thromb Res"},{"key":"R25-20260122","doi-asserted-by":"crossref","first-page":"1244098","DOI":"10.3389\/fphar.2023.1244098","article-title":"Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review.","volume":"14","author":"Atzemian","year":"2023","journal-title":"Front Pharmacol"},{"key":"R26-20260122","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jtha.2023.02.023","article-title":"Major acute cardiovascular events after venous thromboembolism: a meta-analysis of randomized trials.","volume":"21","author":"Becattini","year":"2023","journal-title":"J Thromb Haemost"},{"key":"R27-20260122","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/jth.13626","article-title":"Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention.","volume":"15","author":"Girard","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R28-20260122","first-page":"666","article-title":"Direct oral anticoagulants versus vitamin K antagonists in the treatment of left ventricular thrombosis: a systematic review and meta-analysis.","volume":"70","author":"Condello","year":"2022","journal-title":"Minerva Cardiol Angiol"},{"key":"R29-20260122","doi-asserted-by":"crossref","first-page":"109418","DOI":"10.1016\/j.thromres.2025.109418","article-title":"Efficacy and safety of direct oral anticoagulants compared to no anticoagulation for stroke prevention in atrial fibrillation patients with prior intracranial hemorrhage: a systematic review and meta-analysis.","volume":"253","author":"Ibrahim","year":"2025","journal-title":"Thromb Res"},{"key":"R30-20260122","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/ajhp\/zxae010","article-title":"Risk of bleeding with concomitant use of oral anticoagulants and aspirin: a systematic review and meta-analysis.","volume":"81","author":"Ghule","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"R31-20260122","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"2 Suppl","key":"R32-20260122","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.95.2_Supplement.26S","article-title":"Hemorrhagic complications of long-term anticoagulant therapy.","volume":"95","author":"Levine","year":"1989","journal-title":"Chest"},{"key":"R33-20260122","doi-asserted-by":"crossref","first-page":"e033357","DOI":"10.1136\/bmjopen-2019-033357","article-title":"Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study.","volume":"10","author":"Alfirevic","year":"2020","journal-title":"BMJ Open"},{"key":"R34-20260122","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/M15-0143","article-title":"How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: a practice tool endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society.","volume":"163","author":"Gladstone","year":"2015","journal-title":"Ann Intern Med"},{"key":"R35-20260122","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2016.01.005","article-title":"Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials.","volume":"139","author":"Bova","year":"2016","journal-title":"Thromb Res"},{"key":"R36-20260122","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/heartjnl-2018-313617","article-title":"Extended treatment of venous thromboembolism: a systematic review and network meta-analysis.","volume":"105","author":"Wang","year":"2019","journal-title":"Heart"},{"key":"R37-20260122","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"R38-20260122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/itjm.2013.s8.1","article-title":"Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics.","volume":"7","author":"Masotti","year":"2013","journal-title":"Ital J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:00:59Z","timestamp":1769058059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001175","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}